Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06055244 · ClinicalTrials.gov registry record · Phase 2
Amantadine Therapy for Cognitive Impairment in Long COVID
A Phase 2 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT06055244 is a Phase 2 study that has completed, run by Ohio State University. The registered enrollment target is 64 participants.
The verdict
NCT06055244, a Phase 2 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This study will look at the effects of amantadine on cognitive function in persons with Long COVID. It will also collect specimens to study possible causes of cognitive symptoms in Long COVID, and whether any lab tests can predict who will respond better to amantadine.
Interventions
- DRUG Amantadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-12-07 |
| Est. Completion | 2025-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06055244
The ClinicalTrials.gov registry entry for NCT06055244 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amantadine is the first listed.
NCT06055244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06055244 about?
NCT06055244 is a clinical study titled "Amantadine Therapy for Cognitive Impairment in Long COVID". This study will look at the effects of amantadine on cognitive function in persons with Long COVID. It will also collect specimens to study possible causes of cognitive symptoms in Long COVID, and whether any lab tests can predict who will respond better to amantadine.
What is the current status of trial NCT06055244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-12-07. Estimated completion is 2025-12-29.
What interventions are being tested in trial NCT06055244?
The interventions under investigation include: Amantadine (DRUG).
Who is sponsoring clinical trial NCT06055244?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.